Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland

RATIONALE: There is limited evidence supporting the routine use of palivizumab in paediatric cystic fibrosis (CF) patients to reduce respiratory syncytial virus (RSV) infection and related hospitalisation. Despite this, anti-RSV prophylaxis is increasingly common. This is the first report from Irela...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Multidiscip Respir Med
Prif Awduron: Linnane, Barry, Kiernan, Miranda G., O’Connell, Nuala H., Kearse, Linda, Dunne, Colum P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2015
Pynciau:
Letter to the Editor
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4607252/
https://ncbi.nlm.nih.gov/pubmed/26473032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40248-015-0029-9
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg